References
- Ngo BT-T, Felthaus J, Hein M, et al Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome. Leuk Lymphoma 2010;51:1632–1642.
- Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 2008;121:3853–3857.
- Rodriguez-Pinilla M, Rodriguez-Peralto JL, Hitt R, et al Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer. Clin Cancer Res 2004;10:8486–8492.
- Bartelink H, Begg AC, Martin JC, et al Translational research offers individually tailored treatments for cancer patients. Cancer J Sci Am 2000;6:2–10.
- Alizadeh AA, Bohen SP, Lossos C, et al Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha. Leuk Lymphoma 2010;51:1200–1216.
- He J, Shen D, Chung DU, et al Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy. Int J Oncol 2009;35:683–692.
- Dann EJ, Bar-Shalom R, Tamir A, et al A functional dynamic scoring model to elucidate the significance of post-induction interim F18FDG-PET/CT scanning in patients with Hodgkin lymphoma. Haematologica 2010 Apr 21. [Epub ahead of print]
- Miyanaga A, Gemma A, Noro R, et al Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 2008;7:1923–1930.
- Ogawa K, Murayama S, Mori M. Predicting the tumor response to radiotherapy using microarray analysis (Review). Oncol Rep 2007;18:1243–1248.
- Hsu DS, Balakumaran BS, Acharya CR, et al Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 2007;25:4350–4357.
- Dietel M, Sers C. Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch 2006;448:744–755.
- Treon SP, Hansen M, Branagan AR, et al Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23:474–481.
- Derijks LJ, Wong DR. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr Pharm Des 2010;16:145–154.
- Afzal S, Jensen SA, Vainer B, et al MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol 2009;20:1660–1666.
- Foley KF, Quigley DI. Pharmacogenomic potential of psychiatric medications and CYP2D6. MLO Med Lab Obs 2010;42:32–34.
- Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010 Apr 20. [Epub ahead of print]